Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation.

ABSTRACT:

Purpose

To assess the effectiveness of topical and subconjunctival bevacizumab in suppressing vascularization in graft and host bed after high-risk corneal transplantation.

Design

Secondary analysis of prospective, randomized, double-blind, placebo-controlled multicentric clinical trial.

Participants

The study includes patients aged > 18 years who underwent high-risk penetrating keratoplasty, which was defined as corneal vascularization in ≥ 1 quadrants of the corneal graft and host bed, excluding the limbus.

Methods

Patients were randomized to treatment and control groups. The patients in the treatment group received subconjunctival injection of bevacizumab (2.5 mg/0.1 ml) on the day of the procedure, followed by topical bevacizumab (10 mg/ml) 4 times per day

SUBMITTER: Dohlman TH 

PROVIDER: S-EPMC11046200 | biostudies-literature | 2024 Jul-Aug

REPOSITORIES: biostudies-literature